Mandibular  ||| S:0 E:11 ||| JJ
lateral  ||| S:11 E:19 ||| JJ
shift  ||| S:19 E:25 ||| NN
induces  ||| S:25 E:33 ||| VBZ
the  ||| S:33 E:37 ||| DT
increased  ||| S:37 E:47 ||| JJ
expression  ||| S:47 E:58 ||| NN
of  ||| S:58 E:61 ||| IN
TGF-β ||| S:61 E:66 ||| NNP
,  ||| S:66 E:68 ||| ,
VEGF ||| S:68 E:72 ||| NNP
,  ||| S:72 E:74 ||| ,
and  ||| S:74 E:78 ||| CC
Col-II  ||| S:78 E:85 ||| JJ
in  ||| S:85 E:88 ||| IN
the  ||| S:88 E:92 ||| DT
condyle  ||| S:92 E:100 ||| NN
of  ||| S:100 E:103 ||| IN
rat  ||| S:103 E:107 ||| JJ
temporomandibular  ||| S:107 E:125 ||| NNS
joints  ||| S:125 E:132 ||| VBP
The  ||| S:132 E:136 ||| DT
present  ||| S:136 E:144 ||| JJ
study  ||| S:144 E:150 ||| NN
evaluates  ||| S:150 E:160 ||| VBZ
histologic  ||| S:160 E:171 ||| JJ
changes  ||| S:171 E:179 ||| NNS
to  ||| S:179 E:182 ||| TO
and  ||| S:182 E:186 ||| CC
expression  ||| S:186 E:197 ||| NN
of  ||| S:197 E:200 ||| IN
angiogenic  ||| S:200 E:211 ||| JJ
factors  ||| S:211 E:219 ||| NNS
in  ||| S:219 E:222 ||| IN
rats  ||| S:222 E:227 ||| NNS
with  ||| S:227 E:232 ||| IN
mandibular  ||| S:232 E:243 ||| JJ
functional  ||| S:243 E:254 ||| JJ
shift  ||| S:254 E:260 ||| NN
( ||| S:260 E:261 ||| -LRB-
MFS ||| S:261 E:264 ||| NNP
) ||| S:264 E:265 ||| -RRB-
.  ||| S:265 E:267 ||| .
After  ||| S:267 E:273 ||| IN
1 ||| S:273 E:274 ||| CD
,  ||| S:274 E:276 ||| ,
2 ||| S:276 E:277 ||| CD
,  ||| S:277 E:279 ||| ,
and  ||| S:279 E:283 ||| CC
4  ||| S:283 E:285 ||| CD
weeks  ||| S:285 E:291 ||| NNS
of  ||| S:291 E:294 ||| IN
MFS ||| S:294 E:297 ||| NNP
,  ||| S:297 E:299 ||| ,
rats  ||| S:299 E:304 ||| NNS
in  ||| S:304 E:307 ||| IN
the  ||| S:307 E:311 ||| DT
experimental  ||| S:311 E:324 ||| JJ
and  ||| S:324 E:328 ||| CC
control  ||| S:328 E:336 ||| NN
groups  ||| S:336 E:343 ||| NNS
were  ||| S:343 E:348 ||| VBD
killed ||| S:348 E:354 ||| VBN
.  ||| S:354 E:356 ||| .
Histologic  ||| S:356 E:367 ||| JJ
micrographs  ||| S:367 E:379 ||| NN
of  ||| S:379 E:382 ||| IN
the  ||| S:382 E:386 ||| DT
ipsilateral  ||| S:386 E:398 ||| JJ
condyle  ||| S:398 E:406 ||| JJ
cartilage  ||| S:406 E:416 ||| NN
were  ||| S:416 E:421 ||| VBD
obtained ||| S:421 E:429 ||| VBN
.  ||| S:429 E:431 ||| .
The  ||| S:431 E:435 ||| DT
localization  ||| S:435 E:448 ||| NN
and  ||| S:448 E:452 ||| CC
expression  ||| S:452 E:463 ||| NN
of  ||| S:463 E:466 ||| IN
vascular  ||| S:466 E:475 ||| JJ
endothelial  ||| S:475 E:487 ||| JJ
growth  ||| S:487 E:494 ||| NN
factor  ||| S:494 E:501 ||| NN
( ||| S:501 E:502 ||| -LRB-
VEGF ||| S:502 E:506 ||| NNP
) ||| S:506 E:507 ||| -RRB-
,  ||| S:507 E:509 ||| ,
transforming  ||| S:509 E:522 ||| VBG
growth  ||| S:522 E:529 ||| NN
factor  ||| S:529 E:536 ||| NN
beta  ||| S:536 E:541 ||| NN
( ||| S:541 E:542 ||| -LRB-
TGF-β ||| S:542 E:547 ||| NNP
) ||| S:547 E:548 ||| -RRB-
,  ||| S:548 E:550 ||| ,
and  ||| S:550 E:554 ||| CC
type-II  ||| S:554 E:562 ||| JJ
collagen  ||| S:562 E:571 ||| NN
( ||| S:571 E:572 ||| -LRB-
Col-II ||| S:572 E:578 ||| NNP
)  ||| S:578 E:580 ||| -RRB-
in  ||| S:580 E:583 ||| IN
temporomandibular  ||| S:583 E:601 ||| JJ
joints  ||| S:601 E:608 ||| NNS
( ||| S:608 E:609 ||| -LRB-
TMJs ||| S:609 E:613 ||| NNP
)  ||| S:613 E:615 ||| -RRB-
were  ||| S:615 E:620 ||| VBD
evaluated  ||| S:620 E:630 ||| VBN
through  ||| S:630 E:638 ||| IN
immunohistochemical  ||| S:638 E:658 ||| JJ
staining ||| S:658 E:666 ||| NN
.  ||| S:666 E:668 ||| .
The  ||| S:668 E:672 ||| DT
results  ||| S:672 E:680 ||| NNS
showed  ||| S:680 E:687 ||| VBD
that  ||| S:687 E:692 ||| DT
structural  ||| S:692 E:703 ||| JJ
changes  ||| S:703 E:711 ||| NNS
in  ||| S:711 E:714 ||| IN
the  ||| S:714 E:718 ||| DT
condyle  ||| S:718 E:726 ||| JJ
cartilage  ||| S:726 E:736 ||| NN
could  ||| S:736 E:742 ||| MD
be  ||| S:742 E:745 ||| VB
observed  ||| S:745 E:754 ||| VBN
2  ||| S:754 E:756 ||| CD
weeks  ||| S:756 E:762 ||| NNS
after  ||| S:762 E:768 ||| IN
MFS ||| S:768 E:771 ||| NNP
.  ||| S:771 E:773 ||| .
TGF-β  ||| S:773 E:779 ||| JJ
expression  ||| S:779 E:790 ||| NN
reached  ||| S:790 E:798 ||| VBD
its  ||| S:798 E:802 ||| PRP$
peak  ||| S:802 E:807 ||| NN
2  ||| S:807 E:809 ||| CD
weeks  ||| S:809 E:815 ||| NNS
post-MFS ||| S:815 E:823 ||| JJ
,  ||| S:823 E:825 ||| ,
whereas  ||| S:825 E:833 ||| IN
VEGF  ||| S:833 E:838 ||| NNP
and  ||| S:838 E:842 ||| CC
Col-II  ||| S:842 E:849 ||| NNP
reached  ||| S:849 E:857 ||| VBD
their  ||| S:857 E:863 ||| PRP$
peaks  ||| S:863 E:869 ||| JJ
4  ||| S:869 E:871 ||| CD
weeks  ||| S:871 E:877 ||| NNS
posttreatment ||| S:877 E:890 ||| VBD
.  ||| S:890 E:892 ||| .
Compressive  ||| S:892 E:904 ||| NNP
forces  ||| S:904 E:911 ||| VBZ
applied  ||| S:911 E:919 ||| VBN
to  ||| S:919 E:922 ||| TO
the  ||| S:922 E:926 ||| DT
TMJ  ||| S:926 E:930 ||| NNP
could  ||| S:930 E:936 ||| MD
enhance  ||| S:936 E:944 ||| VB
the  ||| S:944 E:948 ||| DT
expressions  ||| S:948 E:960 ||| NNS
of  ||| S:960 E:963 ||| IN
VEGF ||| S:963 E:967 ||| NNP
,  ||| S:967 E:969 ||| ,
TGF-β ||| S:969 E:974 ||| NNP
,  ||| S:974 E:976 ||| ,
and  ||| S:976 E:980 ||| CC
Col-II ||| S:980 E:986 ||| JJ
,  ||| S:986 E:988 ||| ,
and  ||| S:988 E:992 ||| CC
activate  ||| S:992 E:1001 ||| JJ
angiogenesis ||| S:1001 E:1013 ||| NN
.  ||| S:1013 E:1015 ||| .
The  ||| S:1015 E:1019 ||| DT
proteins  ||| S:1019 E:1028 ||| NNS
appear  ||| S:1028 E:1035 ||| VBP
to  ||| S:1035 E:1038 ||| TO
play  ||| S:1038 E:1043 ||| VB
important  ||| S:1043 E:1053 ||| JJ
roles  ||| S:1053 E:1059 ||| NNS
in  ||| S:1059 E:1062 ||| IN
the  ||| S:1062 E:1066 ||| DT
remodeling  ||| S:1066 E:1077 ||| NN
of  ||| S:1077 E:1080 ||| IN
the  ||| S:1080 E:1084 ||| DT
TMJ ||| S:1084 E:1087 ||| NNP
.  ||| S:1087 E:1089 ||| .
